- Report
- April 2025
- 250 Pages
Global
From €4081EUR$4,490USD£3,466GBP
- Report
- January 2025
- 100 Pages
Global
From €5408EUR$5,950USD£4,592GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1818EUR$2,000USD£1,544GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1136EUR$1,250USD£965GBP
- Report
- June 2024
- 200 Pages
Global
From €7226EUR$7,950USD£6,136GBP
- Report
- January 2025
- 180 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- April 2025
- 262 Pages
Global
From €6358EUR$6,995USD£5,399GBP
- Report
- February 2025
- 138 Pages
Global
From €2000EUR$2,357USD£1,758GBP
- Report
- May 2024
- 420 Pages
Global
From €2727EUR$3,000USD£2,316GBP
- Report
- April 2025
- 203 Pages
Global
From €4227EUR$4,650USD£3,589GBP
- Report
- October 2024
- 181 Pages
Global
From €2113EUR$2,325USD£1,795GBP
€4227EUR$4,650USD£3,589GBP
- Report
- September 2024
- 89 Pages
Global
From €4227EUR$4,650USD£3,589GBP
- Report
- July 2024
- 335 Pages
Global
From €4499EUR$4,950USD£3,821GBP
- Report
- March 2025
- 180 Pages
Global
From €3222EUR$3,545USD£2,736GBP
€3580EUR$3,939USD£3,040GBP
- Report
- October 2024
- 192 Pages
Global
From €3222EUR$3,545USD£2,736GBP
€3580EUR$3,939USD£3,040GBP
- Report
- October 2024
- 184 Pages
Global
From €3222EUR$3,545USD£2,736GBP
€3580EUR$3,939USD£3,040GBP
- Report
- October 2024
- 197 Pages
Global
From €3222EUR$3,545USD£2,736GBP
€3580EUR$3,939USD£3,040GBP
- Report
- October 2024
- 196 Pages
Global
From €3222EUR$3,545USD£2,736GBP
€3580EUR$3,939USD£3,040GBP
- Report
- October 2024
- 188 Pages
Global
From €3222EUR$3,545USD£2,736GBP
€3580EUR$3,939USD£3,040GBP
- Report
- October 2024
- 199 Pages
Global
From €3222EUR$3,545USD£2,736GBP
€3580EUR$3,939USD£3,040GBP

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more